3.02
Schlusskurs vom Vortag:
$2.95
Offen:
$2.93
24-Stunden-Volumen:
623.01K
Relative Volume:
0.39
Marktkapitalisierung:
$214.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-0.9152
EPS:
-3.3
Netto-Cashflow:
$-167.04M
1W Leistung:
-0.33%
1M Leistung:
+33.63%
6M Leistung:
+39.81%
1J Leistung:
+7.86%
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Firmenname
Ventyx Biosciences Inc
Sektor
Branche
Telefon
(858) 945-2393
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Vergleichen Sie VTYX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
VTYX
Ventyx Biosciences Inc
|
3.02 | 215.62M | 0 | -192.96M | -167.04M | -3.30 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-03-12 | Hochstufung | Oppenheimer | Perform → Outperform |
2024-03-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-11-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-11-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2023-11-07 | Herabstufung | Oppenheimer | Outperform → Perform |
2023-11-07 | Herabstufung | Stifel | Buy → Hold |
2023-11-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
2023-03-21 | Eingeleitet | Wells Fargo | Overweight |
2022-12-19 | Eingeleitet | Goldman | Buy |
2022-11-17 | Eingeleitet | Morgan Stanley | Overweight |
2022-09-07 | Eingeleitet | Stifel | Buy |
2022-09-01 | Eingeleitet | H.C. Wainwright | Buy |
2022-05-09 | Eingeleitet | Credit Suisse | Outperform |
2022-03-31 | Eingeleitet | Canaccord Genuity | Buy |
2022-02-01 | Eingeleitet | Oppenheimer | Outperform |
2021-11-15 | Eingeleitet | Jefferies | Buy |
2021-11-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten
What analysts say about Ventyx Biosciences Inc. stockAccelerated earnings growth - jammulinksnews.com
Ventyx Biosciences Inc. Stock Analysis and ForecastPowerful market insights - jammulinksnews.com
Is Ventyx Biosciences Inc. a good long term investmentTremendous return rates - jammulinksnews.com
Why Ventyx Biosciences Inc. stock attracts strong analyst attentionSmart Return Focused Trading - Newser
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth? - Yahoo Finance
What drives Ventyx Biosciences Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
What makes Ventyx Biosciences Inc. stock price move sharplyFree Insider Trading Tips - Newser
How Ventyx Biosciences Inc. stock performs during market volatilityAlpha Stock Ideas - Newser
Wealth Enhancement Advisory Services LLC Invests $28,000 in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Analyzing the Impact of Earnings Reports on Ventyx Biosciences Inc Inc. (VTYX) Price Performance - investchronicle.com
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Shareholders - ACCESS Newswire
Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000E Index - MarketScreener
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Rhumbline Advisers - Defense World
Canaccord maintains buy rating on Ventyx stock after positive trial results - Investing.com
Ventyx stock steady as Parkinson’s drug shows biomarker reductions By Investing.com - Investing.com India
Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s - Yahoo Finance
Ventyx Therapeutics' VTX3232: A Neuroinflammation Breakthrough with Orphan Drug Pricing Power - AInvest
Ventyx Biosciences Inc’s Mixed Bag: Down -9.22% in 6 Months, Down 58.21% in 30 Days - investchronicle.com
Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results - MSN
Ventyx Biosciences Announces Positive Top-Line Data from - GlobeNewswire
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study - MarketScreener
Ventyx reports positive Phase 2a results for Parkinson’s drug - Investing.com
Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m - Yahoo.co
Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives - MarketWatch
Ventyx posts mid-stage trial win for Parkinson’s drug (VTYX) - Seeking Alpha
Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data - Investing.com Canada
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson'S Disease - marketscreener.com
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease - TradingView
Ventyx reports positive Phase 2a results for Parkinson’s drug By Investing.com - Investing.com India
VTYX Trading Halted as Market Awaits News Update | VTYX Stock News - GuruFocus
Piper Sandler maintains $21 target on Ventyx stock By Investing.com - Investing.com Nigeria
Traders Buy Large Volume of Ventyx Biosciences Call Options (NASDAQ:VTYX) - Defense World
Ventyx Biosciences reports annual meeting results By Investing.com - Investing.com India
Ventyx Biosciences reports annual meeting results - Investing.com
Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):